• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Lupus Nephritis
    • Multiple Sclerosis
    • Myasthenia Gravis
    • Stiff Person Syndrome
    • Systemic Sclerosis
  • Inside Kyverna
    • Leadership
    • Scientific Advisory Board
    • Mission & Values
  • Education & Events
    • Events
    • Publications
    • Multimedia
  • Investors
  • News
  • Careers
  • Contact
← Back

Browse Jobs

Clinical

Sr. Clinical Trial Manager

Remote
View

Sr. Medical Director, Clinical Development

Remote
View

Commercial

VP, Global Market Access

Emeryville, CA
View

Project Management

Executive Director, Lifecycle Lead

Remote
View

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Education & Events
  • Investors
  • Careers
  • Contact

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress